Eloxx Pharmaceuticals, Inc.NASDAQ: ELOX

ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity

· Issued by Eloxx Pharmaceuticals, Inc.

Net loss widened to $3.8M in Q1 2026 as R&D and G&A expenses surged, with cash reserves of $6.4M deemed insufficient for the next year. The company eliminated all debt via equity conversions but faces substantial going concern risks and is seeking additional capital.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Eloxx Pharmaceuticals

All Eloxx Pharmaceuticals news releases